The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins, including
- Interventional Agents—therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins, such as imaging and skin test reagents.
- Biopharmaceutical Products—therapeutics that are derived from biotechnology processes, such as monoclonal antibodies and derivatives of monoclonal antibodies; recombinant proteins; peptides; nucleic acid based vectors (siRNA, plasmids); and live, modified-live and/or attenuated entities.
Content last reviewed on April 20, 2016